Source: Annual Congress 2009 - Smoking cessation



Rating:

Share or cite this content

Citations should be made in the following way:
K. Eleftheriou, S. Vakali, A. Florou, D. Mihailidis, C. Gratsiopu, C. Roussos (Athens, Greece). Effectiveness of treatment with varenicline in smokers with cardiovascular diseases (CVD). Eur Respir J 2009; 34: Suppl. 53, 4275

Member's Comments

No comment yet.

Related content which might interest you: Use of varenicline in the treatment of smokers with cardiovascular disease Source: Annual Congress 2013 –Smoking cessation Year: 2013 Smoking cessation compared to treatment of COPD and other smoking-related diseases using cost-effectiveness evidence Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Source: Eur Respir Monogr 2020; 88: 66-81 Year: 2020 Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Smoking cessation in COPD patients (with comorbidities) Source: International Congress 2017 – PG14 Smoking cessation in patients with respiratory diseases Year: 2017 Comparison of effectiveness of varenicline and NRTs in smoking cessation in patients with chronic diseases Source: Annual Congress 2008 - Smoking cessation and new tobacco uses Year: 2008 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Comparison of osteoporosis in male smokers with or without COPD Source: International Congress 2016 – Smoking-related diseases Year: 2016 Influence of respiratory and cardiovascular diseases on smoking cessation. Source: International Congress 2017 – Smoking and health hazards Year: 2017 Effectiveness of vaccination of patients with combination of COPD and coronary heart disease (CHD) Source: International Congress 2015 – Different data in COPD Year: 2015 The cost-effectiveness of antidepressants for smoking cessation in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 801s Year: 2006 Do cardiovascular drugs reduce mortality in patients with COPD in daily practice? A study in primary care Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 Obesity, smoking and gender type as cardiovascular risk factors among COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Frequency of occurrence of risk factors of cardiovascular diseases and assessment of the total cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Source: Eur Respir J 2008; 32: 962-969 Year: 2008 Effectiveness of smoking cessation in patients with psychiatric disease Source: Annual Congress 2012 - Tobacco comorbidity Year: 2012 Co-morbidities of adult smokers at risk of COPD evaluated in a 6-year prospective study Source: International Congress 2015 – COPD: notable points Year: 2015